Spots Global Cancer Trial Database for oropharyngeal squamous cell carcinoma
Every month we try and update this database with for oropharyngeal squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ex Vivo 3D-ultrasound for Oropharyngeal Cancer | NCT06314711 | Oropharyngeal S... | Ultrasound | 18 Years - | Rigshospitalet, Denmark | |
| Oral HPV Infection in Young Men | NCT00897273 | Head and Neck C... Infection Precancerous Co... | comparative gen... gene expression... study of socioe... evaluation of c... study of high r... | 18 Years - 21 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | NCT06084845 | Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biospecimen Col... Carboplatin Chest Radiograp... Cisplatin Computed Tomogr... Image Guided Ra... Intensity-Modul... Magnetic Resona... Positron Emissi... Xevinapant | 18 Years - | Eastern Cooperative Oncology Group | |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | NCT03611205 | Oropharyngeal S... HPV Positive Or... | Computed Tomogr... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | NCT04572100 | Oropharyngeal S... | Transoral Robot... Chemotherapy an... Chemotherapy an... Paclitaxel Carboplatin | 18 Years - | University of Chicago | |
| Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer | NCT00003139 | Head and Neck C... Oral Complicati... | pilocarpine hyd... Placebo | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse | NCT06138483 | Oropharyngeal S... | 18 Years - | Centro di Riferimento Oncologico - Aviano | ||
| The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | NCT05522881 | Oropharyngeal S... | 20 Years - | National Health Research Institutes, Taiwan | ||
| Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC | NCT01874171 | Oropharyngeal S... | Cisplatin Cetuximab | 18 Years - | University of Warwick | |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | NCT03258554 | Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Pathologic Stag... Squamous Cell C... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph... | Cetuximab Durvalumab Intensity-Modul... Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | NCT04220749 | Head and Neck C... Oropharyngeal S... | Radiation Trans-Oral Surg... | 18 Years - | Lawson Health Research Institute | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | NCT04220749 | Head and Neck C... Oropharyngeal S... | Radiation Trans-Oral Surg... | 18 Years - | Lawson Health Research Institute | |
| Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | NCT06323460 | Clinical Stage ... Clinical Stage ... Oropharyngeal S... | Biospecimen Col... Carboplatin Cisplatin Computed Tomogr... External Beam R... Paclitaxel Positron Emissi... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | NCT04718415 | Oral Squamous C... Oropharyngeal S... | sintilimab, pac... Surgical resect... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma | NCT03727594 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 95 Years | University Hospital of Ferrara | ||
| Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | NCT04852328 | Oropharyngeal S... | CUE-101 | 18 Years - | Washington University School of Medicine | |
| Post-treatment Surveillance in HPV+ Oropharyngeal SCC | NCT04965792 | HPV Oropharyngeal S... | Screening | 18 Years - | Dana-Farber Cancer Institute | |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | NCT03952585 | Basaloid Squamo... Clinical Stage ... Clinical Stage ... Oropharyngeal S... Papillary Squam... Pathologic Stag... Pathologic Stag... Squamous Cell C... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Fludeoxyglucose... Image Guided Ra... Intensity-Modul... Magnetic Resona... Nivolumab Positron Emissi... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Validation of a Screening Tool in Geriatric Oncology | NCT00963911 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Lymphoma Prostate Cancer | Geriatric scree... Multidimensiona... | 70 Years - 120 Years | Institut Bergonié | |
| Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. | NCT05333523 | Laryngeal Squam... Hypopharynx Squ... Oropharyngeal S... | Sentinel lymph ... Standard electi... | 18 Years - | Radboud University Medical Center | |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | NCT02156180 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 90 Years | Queensland Centre of Excellence for Head and Neck Cancer | ||
| Shortened Course Adjuvant Radiotherapy Following TORS | NCT05714657 | Oropharyngeal S... | adjuvant radiot... | 18 Years - 99 Years | Abramson Cancer Center at Penn Medicine | |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | NCT05419089 | HPV-positive Or... | Robotic surgery | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | NCT05136196 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | NCT05136196 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | NCT05522881 | Oropharyngeal S... | 20 Years - | National Health Research Institutes, Taiwan | ||
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | NCT03077243 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin (or a... Assessment for ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | NCT05419089 | HPV-positive Or... | Robotic surgery | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | NCT02156180 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 90 Years | Queensland Centre of Excellence for Head and Neck Cancer | ||
| Oropharynx (OPX) Biomarker Trial | NCT06356272 | Clinical Stage ... Clinical Stage ... Metastatic Orop... Oropharyngeal S... Recurrent Oroph... Stage III Oroph... Stage IV Oropha... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Oropharynx (OPX) Biomarker Trial | NCT06356272 | Clinical Stage ... Clinical Stage ... Metastatic Orop... Oropharyngeal S... Recurrent Oroph... Stage III Oroph... Stage IV Oropha... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca | NCT01530997 | Carcinoma, Squa... Head and Neck N... Oropharyngeal N... | Intensity Modul... Cisplatin Limited surgica... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | NCT03258008 | Malignant Neopl... Malignant Neopl... Oropharyngeal C... | Utomilumab ISA101b | 18 Years - | M.D. Anderson Cancer Center | |
| Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | NCT03618134 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Human Papilloma... Oropharyngeal S... p16 Positive Ne... Pathologic Stag... Pathologic Stag... Pathologic Stag... | Durvalumab Modified Radica... Quality-of-Life... Questionnaire A... Stereotactic Bo... Transoral Robot... Tremelimumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | NCT04718415 | Oral Squamous C... Oropharyngeal S... | sintilimab, pac... Surgical resect... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer | NCT00003139 | Head and Neck C... Oral Complicati... | pilocarpine hyd... Placebo | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Post-treatment Surveillance in HPV+ Oropharyngeal SCC | NCT04965792 | HPV Oropharyngeal S... | Screening | 18 Years - | Dana-Farber Cancer Institute | |
| Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | NCT03618654 | Head and Neck S... Oral Cavity Squ... Oropharyngeal S... | Metformin Durvalumab | 18 Years - | Thomas Jefferson University | |
| The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan | NCT05522881 | Oropharyngeal S... | 20 Years - | National Health Research Institutes, Taiwan | ||
| Efficacy and Safety of TORS for SCCA | NCT01819480 | Oropharyngeal S... Supraglottic Sq... | Transoral robot... | 18 Years - | University of Virginia | |
| Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | NCT03410615 | Oropharyngeal S... | Radiation Cisplatin Durvalumab Tremelimumab | 18 Years - | Canadian Cancer Trials Group | |
| Oropharynx (OPX) Biomarker Trial | NCT06356272 | Clinical Stage ... Clinical Stage ... Metastatic Orop... Oropharyngeal S... Recurrent Oroph... Stage III Oroph... Stage IV Oropha... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | NCT06009861 | Oral Squamous C... Oropharyngeal S... | Tislelizumab Albumin-Bound P... Cisplatin | 18 Years - 80 Years | Peking University Hospital of Stomatology | |
| Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | NCT02582008 | Current Smoker Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Nasopharyngeal ... Oral Cavity Squ... Oropharyngeal S... | Bupropion Hydro... Laboratory Biom... Nicotine Replac... Quality-of-Life... Questionnaire A... Varenicline | 18 Years - | Wake Forest University Health Sciences | |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | NCT04564989 | Oropharyngeal S... Carcinoma, Squa... Head and Neck S... Oropharynx Squa... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| InGReS: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study | NCT05393297 | Head and Neck C... | Imaging: Intra-... Intra-treatment... | 18 Years - | Guy's and St Thomas' NHS Foundation Trust | |
| Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | NCT04852328 | Oropharyngeal S... | CUE-101 | 18 Years - | Washington University School of Medicine | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma | NCT02156180 | Oral Cavity Squ... Oropharyngeal S... | 18 Years - 90 Years | Queensland Centre of Excellence for Head and Neck Cancer | ||
| Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | NCT03410615 | Oropharyngeal S... | Radiation Cisplatin Durvalumab Tremelimumab | 18 Years - | Canadian Cancer Trials Group | |
| Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | NCT06009861 | Oral Squamous C... Oropharyngeal S... | Tislelizumab Albumin-Bound P... Cisplatin | 18 Years - 80 Years | Peking University Hospital of Stomatology | |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy | NCT03611205 | Oropharyngeal S... HPV Positive Or... | Computed Tomogr... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) | NCT04801472 | Squamous Cell C... Oropharyngeal S... Oral Cavity Squ... | Optimisation of... | 18 Years - | Institut de cancérologie Strasbourg Europe | |
| Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. | NCT03623646 | Oropharyngeal S... | Chemoradiothera... Immunotherapy +... | 18 Years - | Institut Claudius Regaud |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
